April 13, 2026

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

“Elinzanetant is the first approved targeted agent for [the vasomotor symptoms] that deeply affect the quality of life of breast cancer patients. By helping patients to tolerate better their breast ca...

The ASCO Post

April 09, 2026

Japanese Study Looks at Rates of Cancer Therapy–Related AML

A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (AML) in recent years—especially after breast cancer treatment. 

The ASCO Post

April 08, 2026

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

The ASCO Post

April 07, 2026

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...

The ASCO Post

April 07, 2026

Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer

The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients w...

The ASCO Post

April 06, 2026

Tanning Bed Exposure and Melanoma Risks

Research has elucidated how radiation from tanning beds increases the mutation burden across a broad area of melanocytes, thereby significantly raising the risk of developing melanoma. Findings publis...

The ASCO Post

April 06, 2026

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for mel...

The ASCO Post

April 03, 2026

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

The ASCO Post

April 02, 2026

Financial Hardship and Late-Stage Cancer Diagnosis

In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with ...

The ASCO Post

April 01, 2026

Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer

A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at th...

The ASCO Post